Chronic Oral Treatment with 13-cis-Retinoic Acid (Isotretinoin) or all-trans-Retinoic Acid Does Not Alter Depression-Like Behaviors in Rats
Oral treatment with the anti-acne drug Accutane (isotretinoin, 13-cis-retinoic acid) has been associated with suicide ideation and depression. Here, depression-like behaviors (i.e., behavioral despair and anhedonia) were quantified in adult Sprague-Dawley rats gavaged daily beginning at postnatal da...
Saved in:
Published in | Toxicological sciences Vol. 87; no. 2; pp. 451 - 459 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Oxford University Press
01.10.2005
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Oral treatment with the anti-acne drug Accutane (isotretinoin, 13-cis-retinoic acid) has been associated with suicide ideation and depression. Here, depression-like behaviors (i.e., behavioral despair and anhedonia) were quantified in adult Sprague-Dawley rats gavaged daily beginning at postnatal day (PND) 82 with 13-cis-RA (7.5 or 22.5 mg/kg) or all-trans-retinoic acid (10 or 15 mg/kg ). Tested at PND 130–131 in the Forced Swim Test, 7.5 mg/kg 13-cis-RA marginally decreased immobility and slightly increased climb/struggle durations whereas neither all-trans-retinoic acid group differed from controls. Voluntary saccharin solution (0.03%) intake at PND 102–104 and PND 151–153 was not different from controls in any treated group, although all RA-treated groups had lower intakes. Swim speed in a water maze at PND 180 was similar across groups, indicating no RA-induced differences in physical ability. Open field activity was mildly decreased at PND 91 in 7.5 mg/kg–treated males only, but it was within the control range at PND 119, 147, and 175. Thus, at serum levels similar to those in humans receiving the drug, chronic 13-cis-RA treatment did not severely affect depression-like behaviors in rats. These data do not substantiate the hypothesis of 13-cis-RA-induced depression. |
---|---|
Bibliography: | istex:112336C0AC120A43550AD73A4F652ED8F7CCB6A4 local:kfi262 ark:/67375/HXZ-9MWTCD41-T 1To whom correspondence should be addressed at Division of Neurotoxicology, NCTR/FDA, 3900 NCTR Road, Jefferson, AR 72079. Fax: 870–543–7745. E-mail: sferguson@nctr.fda.gov. ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
ISSN: | 1096-6080 1096-0929 |
DOI: | 10.1093/toxsci/kfi262 |